title: Successful treatment of multidrug-resistant Escherichia coli bacteremia with tigecycline in an acute myeloid leukemia child.
abstract: The multidrug-resistant bacterial infections cause high mortality in immunocompromised patients because of the limited antibacterial choices. Tigecycline, first member of the glycylcyclines, has in vitro activity against a wide variety of organisms, including multidrug-resistant pathogens; however, it has not yet been approved for use in children. Herein, we report a nine-year-old girl with acute myeloid leukemia who was treated successfully with tigecycline due to multidrug-resistant Escherichia coli bacteremia.
authors.affiliation: Division of Pediatric Infectious Diseases, Ankara University Faculty of Medicine, Ankara, Turkey.
authors.forename: Halil
authors.initials: H
authors.lastname: Ozdemir
authors.forename: Ergin
authors.initials: E
authors.lastname: Ciftçi
authors.forename: Adem
authors.initials: A
authors.lastname: Karbuz
authors.forename: Gülşah
authors.initials: G
authors.lastname: Oktay
authors.forename: Derya
authors.initials: D
authors.lastname: Aysev
authors.forename: Gülsan
authors.initials: G
authors.lastname: Yavuz
authors.forename: Erdal
authors.initials: E
authors.lastname: Ince
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D016470:Bacteremia / Q000188:drug therapy*; D002648:Child; D024901:Drug Resistance, Multiple, Bacterial; D004927:Escherichia coli Infections / Q000188:drug therapy*; D005260:Female; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000150:complications*; D008911:Minocycline / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000078304:Tigecycline
chemical_list: D000900:Anti-Bacterial Agents; D000078304:Tigecycline; D008911:Minocycline